NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

OBJECTIVE: This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis. METHODS: In a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Junichi, Ohno, Masako, Kubota, Ryuji, Yokota, Soichiro, Nagai, Takayuki, Tsuyuguchi, Kazunari, Okuda, Yasuhisa, Takashima, Tetsuya, Kamimura, Sayaka, Fujio, Yasushi, Kawase, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Pharmacogenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641305/
https://www.ncbi.nlm.nih.gov/pubmed/23150149
http://dx.doi.org/10.1007/s00228-012-1429-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641305/
https://www.ncbi.nlm.nih.gov/pubmed/23150149
http://dx.doi.org/10.1007/s00228-012-1429-9

Ejemplares similares